You just read:

BioLineRx Announces Dosing of First Patient in Part 2 of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

News provided by

BioLineRx Ltd.

Sep 25, 2019, 07:00 ET